Advances oncology programs from discovery to clinic, developing first-in-class redox therapeutics with completed Phase I and next-generation candidates. Backed by $7M+ NIH funding, applies organoids, spheroids, tumor-on-chip and PDX to design combinations for pancreatic and other solid tumors.